V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004128 | 330002036 | 0 | 103 | Curative (C) | 2014-09-04 | 2014-09-09 | Cetuximab 7 day (Cycle 1) | 2 | Y | 330016210 | CETUXIMAB |
| 330004129 | 330002036 | 1.65 | 89.2 | Curative (C) | 2016-01-10 | 2016-01-13 | OST Euramos 1 Closed Trial - AP | N | N | 330016210 | MAP |
| 330004130 | 330002036 | 1.54 | 79.5 | Disease modification (D) | 2016-08-05 | 2016-08-11 | DA 3 + 10 | 02 | N | 330016210 | DA |
| 330004131 | 330002037 | 1.8 | 51.6 | null | 2013-09-02 | 2013-09-23 | CVP R | Y | N | 330016236 | CVP R |
| 330004132 | 330002037 | 1.79 | 62 | Curative (C) | 2016-08-03 | 2016-08-03 | EW EuroEwing 99 : VIDE | N | N | 330016236 | EURO-EWING |
| 330004133 | 330002037 | 1.68 | null | Palliative (P) | 2017-06-01 | 2017-06-01 | GemCarbo Days 1+8 | N | N | 330016236 | GEMCARBO |
| 330004134 | 330011379 | 0 | 101 | Palliative (P) | 2015-07-17 | 2015-07-30 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 330016242 | CISPLATIN + GEMCITABINE |
| 330004135 | 330011379 | 1.59 | 76 | Neo-adjuvant (N) | 2014-02-24 | 2014-02-28 | CAP | 02 | N | 330016242 | CAP |
| 330004136 | 330011379 | null | null | Curative (C) | 2014-07-18 | 2014-07-18 | EW EuroEwing 99 : VIDE | null | N | 330016242 | EURO-EWING |
| 330004137 | 330002038 | 1.4 | 53.5 | Curative (C) | 2017-04-24 | 2017-04-26 | EW EuroEwing 2012 Arm A VIDE | 02 | N | 330016265 | EURO-EWING |
| 330004138 | 330002039 | 1.66 | 57.5 | Curative (C) | 2017-02-20 | 2017-02-26 | Dox + HD Mtx (post PAM) | 02 | N | 330016269 | DOXORUBICIN + HD MTX |
| 330004139 | 330002040 | 1.5 | null | Adjuvant (A) | null | 2015-07-26 | Carboplatin+Fluorouracil 4 or 5 day | null | null | 330016273 | CARBO + FLUOROURACIL |
| 330004140 | 330002041 | 1.84 | 56.6 | Neo-adjuvant (N) | 2014-02-10 | 2014-02-16 | Carbo F | N | N | 330016278 | CARBO + FLUOROURACIL |
| 330004141 | 330002041 | 1.7 | 75.2 | Neo-adjuvant (N) | 2015-10-27 | 2015-10-29 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 330016278 | CARBO + FLUOROURACIL |
| 330004142 | 330002042 | 1.7 | 77 | Curative (C) | 2013-12-14 | 2014-01-02 | DA 3 + 10 | Y | N | 330016293 | DA |
| 330004143 | 330002042 | null | 49.7 | Palliative (P) | 2015-03-31 | 2015-04-14 | Carboplatin+Fluorouracil 4 or 5 day | null | N | 330016293 | CARBO + FLUOROURACIL |
| 330004144 | 330002043 | null | 151.7 | Curative (C) | 2013-07-16 | 2013-07-25 | EURO-EWING | N | N | 330016302 | EURO-EWING |
| 330004145 | 330002044 | 1.72 | 99.9 | Curative (C) | 2016-04-02 | 2016-04-04 | OST Euramos 1 Closed Trial - AP | 02 | N | 330016303 | MAP |
| 330004146 | 330007117 | 1.59 | 63.2 | Curative (C) | 2013-08-24 | 2013-08-31 | EW EuroEwing 2012 Arm A VIDE | N | N | 330016313 | EURO-EWING |
| 330004147 | 330007117 | 1.8 | 78 | Curative (C) | 2017-05-09 | 2017-05-15 | CETUXIMAB + RT | N | Y | 330016313 | CETUXIMAB + RT |
| 330004148 | 330007117 | 1.66 | 54.7 | Palliative (P) | 2015-12-22 | 2015-12-22 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330016313 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004149 | 330002045 | 0 | 75 | Adjuvant (A) | 2014-08-16 | 2014-08-17 | Dox + HD Mtx (post PAM) | 02 | N | 330016327 | DOXORUBICIN + HD MTX |
| 330004150 | 330002046 | 1.85 | 70 | Adjuvant (A) | 2016-04-21 | 2016-07-07 | CETUXIMAB + RT | N | Y | 330016329 | CETUXIMAB + RT |
| 330004151 | 330007118 | 1.52 | 80 | Neo-adjuvant (N) | 2015-07-09 | 2015-07-24 | CISPLATIN + ETOPOSIDE | N | N | 330016332 | CISPLATIN + ETOPOSIDE |
| 330004152 | 330009859 | 1.46 | 44.6 | Neo-adjuvant (N) | 2014-02-15 | 2014-02-24 | Dox + HD Mtx (post PAM) | N | N | 330016340 | DOXORUBICIN + HD MTX |
| 330004153 | 330009859 | null | 95 | Neo-adjuvant (N) | 2013-09-04 | 2013-09-25 | Dox + HD Mtx (post PAM) | N | N | 330016340 | DOXORUBICIN + HD MTX |
| 330004154 | 330009859 | 1.75 | 81.9 | Neo-adjuvant (N) | 2013-05-11 | 2013-05-27 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330016340 | CISPLATIN + GEMCITABINE |
| 330004155 | 330002047 | 1.59 | 74 | null | null | 2013-10-13 | CETUXIMAB | N | Y | 330016344 | CETUXIMAB |
| 330004156 | 330002048 | 1.69 | 118 | Curative (C) | 2016-11-14 | 2016-11-21 | OST Euramos 1 Closed Trial - AP | N | N | 330016361 | MAP |
| 330004157 | 330002048 | 1.8 | 85 | Curative (C) | 2013-04-24 | 2013-04-29 | MAP | 2 | N | 330016361 | MAP |
| 330004158 | 330002049 | 1.63 | 52.2 | Adjuvant (A) | 2016-12-07 | 2016-12-22 | Dox + HD Mtx (post PAM) | N | N | 330016395 | DOXORUBICIN + HD MTX |
| 330004159 | 330002049 | 1.73 | 62 | Curative (C) | 2015-12-11 | 2015-12-11 | OST Euramos 1 Closed Trial - AP | N | N | 330016395 | MAP |
| 330004160 | 330002049 | 1.66 | 61.7 | Curative (C) | 2017-06-24 | 2017-06-30 | DA 3 + 10 | N | N | 330016395 | DA |
| 330004161 | 330002049 | 1.62 | 54.7 | Curative (C) | null | 2016-01-24 | OST Euramos 1 Closed Trial - AP | N | N | 330016395 | MAP |
| 330004162 | 330002050 | 1.63 | 51 | Not known (9) | 2017-09-08 | 2017-09-12 | CYCLOPHOSPHAMIDE + RITUXIMAB | 2 | N | 330016412 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004163 | 330002051 | null | 54.9 | Curative (C) | 2015-06-11 | 2015-06-12 | EW EuroEwing 2012 Arm A VIDE | 02 | N | 330016418 | EURO-EWING |
| 330004164 | 330002051 | 1.75 | 58 | Curative (C) | 2017-08-04 | 2017-08-21 | OST Euramos 1 Closed Trial - AP | N | N | 330016418 | MAP |
| 330004165 | 330002052 | 0 | 62.5 | Palliative (P) | 2016-01-07 | 2016-01-11 | GemCarbo Days 1+8 | 02 | N | 330016423 | GEMCARBO |
| 330004166 | 330007122 | 1.63 | 92.5 | Curative (C) | 2014-02-27 | 2014-03-11 | OST Euramos 1 Closed Trial - AP | null | N | 330016441 | MAP |
| 330004167 | 330009861 | 1.5 | 63 | Palliative (P) | 2013-10-26 | 2013-11-06 | Cyclophosphamide + Dex + Rituximab | N | N | 330016444 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004168 | 330009861 | 1.73 | 80 | Adjuvant (A) | 2014-04-11 | 2014-04-11 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330016444 | CISPLATIN + GEMCITABINE |
| 330004169 | 330002053 | 1.66 | 76 | Neo-adjuvant (N) | 2017-09-01 | 2017-09-01 | Carbo F | N | N | 330016460 | CARBO + FLUOROURACIL |
| 330004170 | 330002054 | 1.8 | 20.8 | Curative (C) | 2017-02-13 | 2017-03-03 | CETUXIMAB + RT | N | N | 330016474 | CETUXIMAB + RT |
| 330004171 | 330002055 | null | 28.1 | Not known (9) | 2014-12-15 | 2014-12-25 | CVP R | N | N | 330016476 | CVP R |
| 330004172 | 330002055 | 1.8 | null | Adjuvant (A) | 2017-03-05 | 2017-03-12 | EURAMOS TRIAL | 02 | N | 330016476 | EURAMOS TRIAL |
| 330004173 | 330002055 | 1.68 | 66.4 | null | 2017-01-27 | 2017-02-01 | Cetuximab + Radiotherapy Load | N | N | 330016476 | CETUXIMAB + RT |
| 330004174 | 330002055 | 1.53 | 48.6 | Neo-adjuvant (N) | 2017-07-05 | 2017-07-12 | EP 1 2 or 3 day | N | N | 330016476 | CISPLATIN + ETOPOSIDE |
| 330004175 | 330002056 | 1.64 | null | Curative (C) | 2014-10-05 | 2014-10-08 | Cisplatin + Etoposide (3 day) | N | N | 330016497 | CISPLATIN + ETOPOSIDE |
| 330004176 | 330002056 | 1.47 | 62.5 | Neo-adjuvant (N) | 2015-07-13 | 2015-07-15 | Carbo F | N | N | 330016497 | CARBO + FLUOROURACIL |
| 330004177 | 330002057 | null | 81 | Curative (C) | 2015-01-31 | 2015-01-31 | EURO-EWING | N | N | 330016499 | EURO-EWING |